Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. [clinicaltrials_resource:NCT00319748/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
Patients With Tumor Response (Response Evaluation Criteria in Solid Tumors) Who Received All 24 Doses of 852A. [clinicaltrials_resource:NCT00319748/outcome/1]
Bio2RDF identifier
NCT00319748/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00319748/outcome/1
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
population [clinicaltrials_vocabulary:population]
Includes only patients that received all 24 doses of 852A.
One patient did not have a val ...... annot be included in analysis.
One patient did not have recor ...... annot be included in analysis.
One patient did not have value ...... atment, so cannot be included.
Only 5 patients had a value reported at 6 hours after treatment.
Only 9 patients had recorded v ...... and were included in analysis.
Two patients did not have reco ...... annot be included in analysis.
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
Prior to Dose 1 and 6 Hours Post-Dose
Prior to Dose 1 and 6 hours after Dose 1
after 12 weeks (24 doses of 852A)
type [clinicaltrials_vocabulary:type]
alternate
Patients With Tumor Response ( ...... Received All 24 Doses of 852A.
@en
identifier
clinicaltrials_resource:NCT00319748/outcome/1
title
Assessment of anti-tumor activ ...... le Disease = neither PR or PD.
@en
type
label
Patients With Tumor Response ( ...... esource:NCT00319748/outcome/1]
@en